Sugammadex in a Patient with Brugada Syndrome

WOS: 000382992900009PubMed ID: 27366567Brugada Syndrome was first described in 1992 by Pedro Brugada as a genetic syndrome that is characterized by ventricular arrhythmias that may result in sudden cardiac arrest. In particular, a right bundle branch block and ST segment elevation in the right precordial leads are observed. Many perioperative pharmalogical and physiological factors can trigger malignant arrhythmias. Although it is a rare condition, the anaesthestic management of Brugada syndrome is important because of the potentially fatal complications. Many anaesthetics have been administered during the operation of patients with Brugada Syndrome. The use of sugammadex instead of the anaesthetic management of patients with Brugada syndrome is discussed in this study

Sugammadex in a Patient with Brugada Syndrome

WOS: 000382992900009PubMed ID: 27366567Brugada Syndrome was first described in 1992 by Pedro Brugada as a genetic syndrome that is characterized by ventricular arrhythmias that may result in sudden cardiac arrest. In particular, a right bundle branch block and ST segment elevation in the right precordial leads are observed. Many perioperative pharmalogical and physiological factors can trigger malignant arrhythmias. Although it is a rare condition, the anaesthestic management of Brugada syndrome is important because of the potentially fatal complications. Many anaesthetics have been administered during the operation of patients with Brugada Syndrome. The use of sugammadex instead of the anaesthetic management of patients with Brugada syndrome is discussed in this study

A single-center experience with resin adsorption hemoperfusion combined with continuous veno-venous hemofiltration for septic shock patients

Our primary goal was to investigate whether treatment of CVVH-HP in patients with septic shock caused decreased vasoconstrictor and inotropic drug requirements. As a secondary objective, to determine whether CVVH-HP had an effect on inflammatory biomarkers and mortality. 11 septic shock patients who received CVVH-HP treatment within 12 months were included in the study. The following parameters were taken from patients medical records; hemodynamic parameters, infection markers, inotropes and vasopressors use. Also, Intensive care mortality and duration of ICU stay were assessed. The survival rate after the 24 hours from the start of treatment was 63.6% and 28 days survival rate was 36.4%. Four of the remaining seven survivors at the 24 hours were discharged home. CVVH- HP treatment was associated with an increase of mean arterial pressure, reduction of vasoconstrictor/ionotropic requirement, reduction of C-reactive protein and procalcitonin levels. In our retrospective study, we found that patients treated with CVVH-HP treatment had approximately 40% reduction in norepinephrine and dopamine requirement in the first 24 hours and patients had higher mean arterial pressures. [Med-Science 2019; 8(2.000): 390-4

Anesthetic Approach to a Child with Noonan's Syndrome

Noonan syndrome is characterized by fascial and physical features along with congenital heart disease. In these patients, fascial features include short webbed neck, micrognathia, limited mouth opening and high arched palate. Pulmonary stenosis and hypertrophic obstructive cardiomyopathy are highly prevalent in Noonan's syndrome. The anesthetic management is important because of difficult airway and severe cardiac abnormalities. We reported that anesthetic management of a child with Noonan's syndrome. [Cukurova Med J 2015; 40(Suppl 1): 47-50